v3.26.1
Note 14 - Phaseone Divestiture - Held-for-sale (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Net income from discontinued operations, net of taxes $ 11,081 $ 1,527
Total current assets, discontinued operations 0 1,233
Total current liabilities, discontinued operations 0 1,190
Accounts payable and accrued liabilities (37) (57)
(Benefit) Provision for income taxes 244  
Net increase in cash and cash equivalents, discontinued operations 11,133 3,299
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | Wound Care [Member]    
Net income from discontinued operations, net of taxes 530 71
Accounts receivable, net   6
Inventory, net   48
Total current assets, discontinued operations   54
Gross profit 47 111
Non-cash gain on divestiture (500) 0
Research and development 3 40
Accounts receivable 6 6
Accounts payable   43
Total current liabilities, discontinued operations   43
Total operating expenses 3 40
Inventory 43 12
Operating loss 44 71
Accounts payable and accrued liabilities (38) (21)
Gain on divestiture 500 (0)
Net cash (used in) provided by operating activities, discontinued operations 45 68
Proceeds from divestiture 500 0
Net cash provided by investing activities, discontinued operations 500 0
Net increase in cash and cash equivalents, discontinued operations 541 68
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | Wound Care [Member] | Product [Member]    
Net sales 122 258
Net income from discontinued operations, net of taxes 530 71
Non-cash gain on divestiture (500) 0
Gain on divestiture 500 0
Net income from discontinued operations before income taxes 544 71
(Benefit) Provision for income taxes 14 0
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | Wound Care [Member] | Other Revenue [Member]    
Cost of goods sold $ 75 $ 147